Adeno-associated virus (AAV) vectors are a core delivery technology for gene therapy in neurodegenerative disease because they can support durable expression in post-mitotic neural cells while remaining substantially less pathogenic than many alternative viral systems.[@wang2019][@daya2008] Their practical utility in CNS disease depends on capsid tropism, route of administration, immune profile, and manufacturing scalability.[@wang2019][@hudry2019]
Overview
AAV platforms are used across [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis), and [Huntington's disease](/diseases/huntingtons) programs to deliver gene replacement, gene silencing, neurotrophic support, or genome-editing cargo.[@wang2019][@tabrizi2022]
AAV Biology and Serotypes
AAV Structure
Small, non-enveloped icosahedral virus
Single-stranded DNA genome with limited cargo capacity
Helper-virus dependent wild-type replication
Recombinant therapeutic vectors are typically replication-deficient and largely episomal[@daya2008]
Key Serotypes for CNS Delivery
Mechanism of CNS Delivery
Routes of Administration
Intraparenchymal injection: Direct regional brain delivery
Intrathecal delivery: Cerebrospinal-fluid distribution with spinal and meningeal access
Intravenous delivery: Requires BBB-crossing or BBB-bypassing vector properties
Intraventricular delivery: CSF circulation with broader ventricular exposure[@wang2019][@hudry2019]
Cellular Entry and Expression
Receptor-mediated binding and endocytosis
Endosomal trafficking and nuclear import
Second-strand synthesis or self-complementary vector entry
Promoter-driven transgene expression with cell-type dependence[@daya2008]
Applications in Neurodegenerative Diseases
Alzheimer's Disease
Parkinson's Disease
ALS
Huntington's Disease
Advantages of AAV Vectors
Safety Profile
No established human disease phenotype from wild-type AAV
Replication-deficient therapeutic constructs
Lower pathogenicity than many alternative viral vectors
Long-term expression in post-mitotic neural tissue[@wang2019][@daya2008]
Therapeutic Benefits
Single-administration durability
Compatibility with neuron-specific or glia-specific promoters
Broad CNS coverage with appropriate serotype / route selection
Flexibility for gene replacement, silencing, and editing strategies[@wang2019]
Challenges and Limitations
Delivery Challenges
[Blood-brain barrier](/entities/blood-brain-barrier) remains a major constraint
High systemic doses can be required for widespread CNS exposure
Regional injections may still have limited tissue spread
Large-scale manufacturing remains expensive and technically difficult[@wang2019][@hudry2019]
Immunological Concerns
Pre-existing neutralizing antibodies can block transduction
Capsid-specific T-cell responses can reduce durability
Re-dosing is difficult after an initial systemic exposure[@mingozzi2013]
Technical Limitations
Small cargo capacity
Delayed onset relative to direct small-molecule therapy
Off-target transduction and promoter leakage remain relevant risks[@wang2019][@daya2008]
Clinical Trials and Approvals
Approved Gene Therapies Outside Neurodegeneration
Luxturna (AAV2) for RPE65-mediated retinal disease
Zolgensma (AAV9) for spinal muscular atrophy
Additional approvals in non-neurologic indications demonstrate platform maturity[@wang2019]
Ongoing CNS Programs
AAV2-GDNF and AAV2-AADC in Parkinson's disease
AAV-based HTT-lowering programs in Huntington's disease
AAV-mediated silencing approaches in familial ALS[@tabrizi2022][@mingozzi2013]
See Also
[AAV Gene Therapy for Neurodegeneration](/therapeutics/aav-gene-therapy-neurodegeneration)
[AAV Gene Therapy Vectors for Neurodegenerative Diseases](/therapeutics/aav-cns-gene-therapy)
[Gene Therapy for Neurodegenerative Diseases](/therapeutics/gene-therapy)
[CRISPR Gene Editing for Neurodegenerative Diseases](/therapeutics/crispr-gene-editing)
Background
The study of Aav Vectors In Neurodegenerative Disease Gene Therapy has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
External Links
[PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
[Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
[Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data
References
[Wang D, Tai PWL, Gao G, Adeno-associated virus vector as a platform for gene therapy delivery (2019)](https://doi.org/10.1038/s41573-019-0012-7)
[Daya S, Berns KI, Gene therapy using adeno-associated virus vectors (2008)](https://doi.org/10.1128/CMR.00008-08)
[Hudry E, Vandenberghe LH, Therapeutic AAV Gene Transfer to the Nervous System: A Clinical Reality (2019)](https://doi.org/10.1016/j.neuron.2019.02.017)
[Tabrizi SJ, Leavitt BR, Kordasiewicz H, et al, First-in-Human Study of AAV5-miHTT Gene Therapy for Huntington's Disease (2022)](https://doi.org/10.1002/ana.26308)
[Mingozzi F, High KA, Immune responses to AAV vectors: overcoming barriers to successful gene therapy (2013)](https://doi.org/10.1182/blood-2013-01-306647)
Related Hypotheses
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
[Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: BDNF